54307-67-4

Usage

Uses

Used in Pharmaceutical Industry:
Benzene, [[2-bromo-1-(chloromethyl)ethoxy]methyl]is used as a pharmaceutical intermediate for the synthesis of various drugs and medicinal compounds. Its unique structure, containing a bromine atom, a chlorine atom, and a benzene ring, allows for the development of new pharmaceutical agents with specific therapeutic properties.
Used in Liquid Crystal Industry:
Benzene, [[2-bromo-1-(chloromethyl)ethoxy]methyl]is also used as a liquid crystal compound in the production of liquid crystal displays (LCDs) and other electronic devices. Its molecular structure contributes to the unique optical and electrical properties of liquid crystals, making it a valuable component in the development of advanced display technologies.
However, it is important to handle Benzene, [[2-bromo-1-(chloromethyl)ethoxy]methyl]with caution due to its potential harmful effects on health and the environment, as well as its flammability. Additional research and testing may be needed to further understand the properties and potential uses of this chemical compound, ensuring its safe and effective application in various industries.

Upstream product

• 100-39-0 benzyl bromide 
• 106-89-8 epichlorohydrin 

Downstream Products

• 54166-15-3 diethyl 3-(benzyloxy)cyclobutane-1,1-dicarboxylate 
• 180205-43-0 3-(benzyloxy)-1-carbethoxycyclobutane-1-carboxylic acid 
• 413597-66-7 ethyl 3-(benzyloxy)-1-<<(tert-butyloxy)carbonyl>amino>cyclobutane-1-carboxylate 
• 222727-29-9 1-amino-3-benzyloxycyclobutane-1-carboxylic acid 
• 191110-49-3 2-(benzyloxy)-5,7-diazaspiro[3.4]octane-6,8-dione 
• 191110-48-2 3-benzyloxycyclobutane-1,1-dicarboxamine 
• 222727-31-3 1-t-butyl carbamate-3-benzyloxy-1-cyclobutane-1-carboxylic acid 
• 222727-33-5 1-t-butyl carbamate-3-benzyloxy-1-cyclobutane-1-carboxylic acid methyl ester 
• 20061-24-9 [3-benzyloxy-1-(hydroxymethyl)cyclobutyl]methanol 
• 84182-46-7 3-(benzyloxy)cyclobutane-1,1-dicarboxylic acid 
• 4958-02-5 3-(benzyloxy)cyclobutane-1-carboxylic acid 
• 1124175-26-3 3-(benzyloxy)cyclobutane-1-carbonyl chloride 
• 141352-51-4 2-(benzyloxy)-7,7-dimethyl-6,8-dioxaspiro<3.5>nonane 
• 156865-32-6 3-(benzyloxy)cyclobutane-1-methanol 

Relevant academic research and scientific papers

Synthesis and in vitro antitumour activity of carboplatin analogues containing functional handles compatible for conjugation to drug delivery systems

We describe herein the synthesis of a series of carboplatin derivatives with different functional groups at position 3 of the cyclobutane ring. This pharmacomodulation approach aims at facilitating the vectorisation of these analogues, via their subsequen

BENZOFURAN DERIVATIVES FOR THE TREATMENT OF HEPATITIS C

The disclosure provides compounds of formula (I), including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.

Synthesis and anticancer activity of diam(m)ine platinum(II) complexes with 3-oxo-cyclobutane-1,1-dicarboxylate as the leaving group

Four water-soluble dia(m)mine platinum complexes with 3-oxo-cyclobutane- 1,1-dicarboxylate as the leaving group have been synthesized. These compounds were evaluated for their in vitro anticancer activity against three human A549, SK-OV-3, and HT-29 cance

Potent anticancer activity and possible low toxicity of platinum(II) complexes with functionalized 1,1-cyclobutanedicarboxylate as a leaving ligand

Two platinum(II) complexes, DN603 and DN604, were designed and prepared by using 3-oxocyclobutane-1,1-dicarboxylate as a ligand. The compounds were prepared according to the concept that incorporation of a functionalized moiety in the leaving ligand that

COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS

The invention provides compounds and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit or c-kit and PDGFR (PDGFRα, PDGFRβ) kinases.

CYSTEINE PROTEASE INHIBITORS

Compounds of the formula (I) wherein One of A1 and A2 is N-CH3 and the other is CH; R1 is C1-C6alkyl, C1-C6haloalkyl, C3-C6cycloalkyl or oxetan-3-yl, wherein C3-C6cycloalkyl is optionally substituted with one, two or three fluoro or with CF3; R2a and R2b are independently selected from H, halo, C1-C4alkyl, C1-C4haloalkyl and C1- C4alkoxy; R3 is CH3 or F; n is 1, 2, 3 or 4; or a pharmaceutically acceptable salt, hydrate or N-oxide thereof for the use in the prophylaxis and/or treatment of a disorder characterised by inappropriate expression or activation of cathepsin S.

Antitumor platinum(II) complexes containing platinum-based moieties of present platinum drugs and furoxan groups as nitric oxide donors: Synthesis, DNA interaction, and cytotoxicity

Six novel platinum(II) complexes 1-6 bearing different furoxan moieties as nitric oxide (NO) donors have been designed, synthesized, and characterized by elemental analysis and 1H NMR, IR, and ESI-MS spectroscopy. The furoxan groups were introduced to the platinum complexes to release NO, which may take synergic action with the platinum-based moieties on the tumor cells. It was found that all compounds exhibited considerable cytotoxicity against human HCT-116 and SGC-7901 cell lines via DNA binding together with NO-releasing features, especially for compound 3. This finding is in accordance with the previous reports that NO hybrids show higher cytotoxicity against colon cancer cell lines compared with their parent compounds.

Nitric oxide donor-based platinum complexes as potential anticancer agents

Joining forces: Platinum complexes containing organic nitrate ligands were investigated as anticancer agents. The complexes, which were stable in aqueous solution, showed cytotoxicity that was superior to that of the corresponding parent compound (carbopl

CYSTEINE PROTEASE INHIBITORS

Compounds of Formula (II) wherein R1a is H; and R1b is C1-C6alkyl, Carbocyclyl or Het; or R1a and R1b together define a saturated cyclic amine with 3-6 ring atoms; R2a and R

CYSTEINE PROTEASE INHIBITORS

Compounds of the formula (I) wherein R1a is H; and R1b is C1-C6alkyl, Carbocyclyl or Het; or R1a and R1b together define a saturated cyclic amine with 3-6 ring atoms; R2a and Rs